To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
118th Congress
Introduced Nov 7, 2023
Sponsors
Legislative Progress
Introduced
Introduced
Committee
Passed
Nov 7, 2023
Ms. Perez (for herself, Mr. Casten, and Mr. Connolly) introduced …
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology